Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. <AVIR.OQ> expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. AVIR.OQ AVIR.O is expected to show no change in quarterly revenue when it reports results on August 12 for the period ending June 30 2026
LSEG's mean analyst estimate for Atea Pharmaceuticals, Inc. is for a loss of 56 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Atea Pharmaceuticals, Inc. is $8.00, about 52.4% above its last closing price of $5.25
This summary was machine generated August 10 at 20:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM